Navivumab
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2[1].
Product Specifications
CAS Number
[1443004-16-7]
Product Name Alternative
CT-P23
UNSPSC
12352203
Target
Influenza Virus
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/navivumab.html
Purity
99.10
Solubility
10 mM in DMSO
Smiles
[Navivumab]
Molecular Weight
(146.6 kDa)
References & Citations
[1]Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis. 2018 Dec;31 (6) :527-534.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1474575-01 0.02 mg (E-Coli)
Recombinant Pyrococcus abyssi Polyribonucleotide 5'-hydroxyl-kinase PYRAB01840 (PYRAB01840)
Ask
View Details 
MBS1474575-02 0.1 mg (E-Coli)
Recombinant Pyrococcus abyssi Polyribonucleotide 5'-hydroxyl-kinase PYRAB01840 (PYRAB01840)
Ask
View Details MBS1474575-03 0.02 mg (Baculovirus)
Recombinant Pyrococcus abyssi Polyribonucleotide 5'-hydroxyl-kinase PYRAB01840 (PYRAB01840)
Ask
View Details MBS1474575-04 0.02 mg (Mammalian-Cell)
Recombinant Pyrococcus abyssi Polyribonucleotide 5'-hydroxyl-kinase PYRAB01840 (PYRAB01840)
Ask
View Details 
MBS1474575-05 0.1 mg (Baculovirus)
Recombinant Pyrococcus abyssi Polyribonucleotide 5'-hydroxyl-kinase PYRAB01840 (PYRAB01840)
Ask
View Details MBS1474575-06 1 mg (E-Coli)
Recombinant Pyrococcus abyssi Polyribonucleotide 5'-hydroxyl-kinase PYRAB01840 (PYRAB01840)
Ask
View Details